JAB 24114
Alternative Names: JAB-24114Latest Information Update: 24 Mar 2023
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer; Squamous cell cancer